Mariam Alexander
@MariamAlex26
Followers
250
Following
2K
Media
22
Statuses
117
Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed
Joined June 2019
RT @StephenVLiu: Don't miss #DCLung25 - a one-day, @IASLC endorsed comprehensive lung cancer conference on Saturday, October 4th in Washing….
0
2
0
RT @IASLC: The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancer….
0
13
0
Such a treat to discuss this important approval and learn about the history of Sunvozertinib development and trial design and nuances of dose/toxicities from Dr James Yang. Thanks @StephenVLiu @IASLC #lcsm @EGFRResisters.
Watch for this episode of the @IASLC podcast Lung Cancer Considered next week - I discuss the latest FDA approval for lung cancer: sunvozertinib, for lung cancer with an EGFR exon 20 insertion. Great discussion and background with Drs. James Chih-Hsin Yang and @MariamAlex26!
2
1
11
More options for this rare disease. Would this work after zipalertinib (trial pt) @BalazsHalmosMD FDA grants accelerated approval to sunvozertinib for NSCL with EGFR exon 20 insertion mut #lcsm
fda.gov
On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or...
2
2
8
RT @NaglaAKarimMD: We made it to #ASCO25 @ASCO and running in between sessions & meetings @LealTiciana @MariamAlex26 @HinaKhanMD @….
0
5
0
More options!.
🚨 FDA #accelerated approval: Telisotuzumab vedotin💉for advanced non-sq #NSCLC w/ high c-Met overexpression (≥50% 3+ IHC), 1.9 mg/kg q2 weeks.🧬 ORR: 35%.⏱️ DOR: 7.2 months.🔬 Companion Dx: VENTANA MET SP44.Another ADC joins #lcsm toolkit!.@LungCancerRx @OncBrothers @US_FDA
0
2
5
A Sen-sational choice for this important role. Triparna has worked tirelessly to advance our understanding of aggressive lung cancers and will continue to be pivotal in shaping the future of lung cancer research. #lcsm.
I am truly thrilled and humbled to be nominated as a candidate for the @IASLC Board of Directors (Basic Science). @IASLC has been my professional home for nearly a decade—a place that has shaped my journey as a #scientist, #mentor, and #collaborator. I have met some of the most
1
0
3
RT @TLCconference: Get ready for 'Tools for Tomorrow’s Oncologist' at #TexasLung25 starting at 3:30 PM with special guests Drs. Steven Paul….
0
5
0
Thanks @StephenVLiu #TinaCascone @TLCconference for the invitation to speak about ICI toxicities and hang out with the coolest of the cool group #TexasLung25 #lcsm @jillfeldman4 @NarjustFlorezMD @ROsarogiagbon #JenTemel @Ideologyhealth @muschollings @MUSChealth @HemOncWomenDocs.
Getting ready for the stage at 2025 Texas Lung Conference . With @jillfeldman4 and many amazing people . @TLCconference #TLC25
1
1
20
RT @oncodaily: Advances in molecular targets for NSCLC - @NaglaAKarimMD .@MariamAlex26 @StephenVLiu @MUSChealth . .
0
3
0
RT @StephenVLiu: Fantastic multi-disciplinary panel to discuss early stage NSCLC at #DCLung24 with Drs. @SBroderickMD, @CharuAggarwalMD, Ma….
0
2
0
RT @StephenVLiu: Fantastic description of targeted therapy in the early stage lung cancer space from Dr. @MariamAlex26 at #DCLung24. Striki….
0
11
0
RT @NaglaAKarimMD: @MariamAlex26 presents all about before & after molecular targets in resectable NSCLC. Neoadjuvant Target Therapies aw….
0
4
0
SQ Ami is a game changer simplifying delivery of Amivamtamab, reducing health care burden and is preferred by patients with 5 fold reduction in infusion related reactions #paloma3 #WCLC24 @muschollings @MUSChealth.
For US #HCPs at #WCLC24: see Dr. Mariam Alexander (@MariamAlex26) present patient satisfaction & resource utilization results from Phase 3 PALOMA-3 study of subcutaneous EGFRxMET bispecific antibody + 3rd-gen TKI in EGFR-mutated advanced or metastatic non-small cell #LungCancer.
1
1
13
RT @StephenVLiu: FDA approves first perioperative immunotherapy regimen for resectable NSCLC. Based on KEYNOTE 671, #neoadjuvant pembrolizu….
businesswire.com
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRU...
0
53
0
RT @KateEEngelhardt: Good morning from Singapore! @muschollings representing at the #WCLC23 early career workshop 🤩🫁💪🏼 .
0
2
0
RT @StephenVLiu: Adjuvant alectinib significantly improves DFS for resected #ALK NSCLC! Phase III ALINA trial meets primary endpoint, per p….
gene.com
Discover the latest news about our company, our products, our policies, and our people.
0
50
0
So good to catch up with friends! Proud to be a prior @EinsteinMed @MontefioreNYC fellow. Thank you @DrSteveMartin for organizing. The non-Indian Indian food was so yummy esp the mango lassi. #ASCO23.
Monte/Einstein hem/onc-past/present (+future?) at #ASCO23 w special cameo appearances by @luckydoc2 @jsparano @DrHaigentz!.No need to be an Einstein to see what a special group!. (i was told i ordered the most non-Indian Indian food there is for the group- but it looked good, no?
0
0
6
RT @StephenVLiu: Dr. @NaglaAKarimMD presents @SWOG S1929 at #ASCO23: maintenance PARP in SLFN11+ #SCLC. Encouraging data for targeting PARP….
0
21
0